NASDAQ:EVGN Evogene (EVGN) Stock Price, News & Analysis $2.51 -0.21 (-7.72%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Evogene Stock (NASDAQ:EVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evogene alerts:Sign Up Key Stats Today's Range$2.49▼$2.8750-Day Range$2.14▼$4.1652-Week Range$2.14▼$10.40Volume65,615 shsAverage Volume19,828 shsMarket Capitalization$103.45 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewEvogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Evogene Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScoreEVGN MarketRank™: Evogene scored higher than 61% of companies evaluated by MarketBeat, and ranked 419th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvogene has only been the subject of 1 research reports in the past 90 days.Read more about Evogene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evogene is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evogene is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvogene has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Evogene's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.29% of the float of Evogene has been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently decreased by 39.67%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvogene does not currently pay a dividend.Dividend GrowthEvogene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.29% of the float of Evogene has been sold short.Short Interest Ratio / Days to CoverEvogene has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evogene has recently decreased by 39.67%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.30 News SentimentEvogene has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Evogene this week, compared to 1 article on an average week.Search Interest1 people have searched for EVGN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Evogene to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evogene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Evogene is held by insiders.Percentage Held by InstitutionsOnly 10.40% of the stock of Evogene is held by institutions.Read more about Evogene's insider trading history. Receive EVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter. Email Address EVGN Stock News HeadlinesStockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)October 19, 2024 | americanbankingnews.comEvogene-Aktie erreicht 52-Wochen-Tief bei 2,21 US-DollarOctober 17, 2024 | de.investing.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing TechnologyOctober 8, 2024 | prnewswire.comLavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-BiologicalsSeptember 30, 2024 | prnewswire.comEvogene-Aktie erreicht 52-Wochen-Tief bei 2,6 US-DollarSeptember 25, 2024 | de.investing.comEvogene-Aktie erreicht 52-Wochen-Tief bei 2,78September 16, 2024 | de.investing.comEvogene secures $5.5 million in direct offeringAugust 25, 2024 | investing.comSee More Headlines EVGN Stock Analysis - Frequently Asked Questions How have EVGN shares performed this year? Evogene's stock was trading at $8.40 at the beginning of the year. Since then, EVGN stock has decreased by 70.1% and is now trading at $2.51. View the best growth stocks for 2024 here. How were Evogene's earnings last quarter? Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings data on Thursday, August, 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.94. The biotechnology company had revenue of $0.91 million for the quarter. Evogene had a negative net margin of 210.26% and a negative trailing twelve-month return on equity of 72.33%. When did Evogene's stock split? Evogene's stock reverse split on the morning of Thursday, July 25th 2024. The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Evogene's major shareholders? Evogene's top institutional investors include Renaissance Investment Group LLC (0.02%). How do I buy shares of Evogene? Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Tesla (TSLA), NIO (NIO), Palantir Technologies (PLTR), NVIDIA (NVDA), Plug Power (PLUG), Riot Platforms (RIOT) and AquaBounty Technologies (AQB). Company Calendar Last Earnings8/22/2024Today10/24/2024Next Earnings (Estimated)11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Agricultural chemicals Sub-IndustryChemicals Current SymbolNASDAQ:EVGN CUSIPN/A CIK1574565 Webwww.evogene.com Phone(728) 931-1900Fax972-8946-6724Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+378.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,880,000.00 Net Margins-210.26% Pretax Margin-222.60% Return on Equity-72.33% Return on Assets-40.42% Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick Ratio4.24 Sales & Book Value Annual Sales$9.45 million Price / Sales10.95 Cash FlowN/A Price / Cash FlowN/A Book Value$6.96 per share Price / Book0.36Miscellaneous Outstanding Shares41,216,000Free FloatN/AMarket Cap$103.45 million OptionableOptionable Beta1.40 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:EVGN) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.